Archive for the ‘Gene Therapy Research’ Category

Madeline Ostrander is a freelance journalist based in Seattle and the former senior editor of Yes! Magazine. Distributed by Agence Global.

ITS RARE to find someone neutral on the subject of genetically modified food which is, depending on whom you ask, either a risky technology giving Monsanto greater market control, or the heroic invention of scientists who will save us from world hunger.

The last few weeks have brought a flurry of news about scientists and techies trying to save the imperiled orange and our food supply more generally through genetic engineering. A few days ago, The New York Times published an in-depth story about farmers and scientists battling anti-GMO public sentiment to rescue oranges from an epidemic bacterial disease. They were testing a new orange (with a gene taken from spinach) that would resist pathogens.

Earlier this month, an article in Slate suggested genetic engineering could move beyond the ills of corporate agriculture and become an open-source project, as hip and democratic as the operating system Linux. The magazine ran a second story from a vegetarian yoga instructor who had seen the light on GMOs. This author chose to debunk a series of arguments against genetic tinkering, most connected to ick-factors e.g., queasiness over whether animal genes are inserted into plant DNA. The gist of both pieces was that GMOs and genetic property rights should be taken out of corporate control and put into the public domain and the hands of smart, principled scientists.

When genetic engineering is used to decrease pesticide use, to add nutrients to crops in malnourished countries, and otherwise improve the quality of our food products, then its a valuable tool that can contribute to a safe and healthy food supply, wrote the self-described hippie.

It is doubtless true that the world will need smart science and diverse genetic resources to respond to crises like climate change and disease. But to read these stories, one would think that the biggest objections to GMOs were concocted solely by sentimental greenies and organic food growers with outdated sensibilities. From the Times piece:

Some scientists were still fuming about what they saw as the lost potential for social good hijacked both by the activists who opposed genetic engineering and the corporations that failed to convince consumers of its benefits. In many developing countries, concerns about safety and ownership of seeds led governments to delay or prohibit cultivation of needed crops: Zambia, for instance, declined shipments of GMO corn even during a 2002 famine.

Truthfully, the science and the ethics have never been quite so cut and dried.

The Union of Concerned Scientists (or UCS, the nonprofit hatched out of MIT more than 40 years ago) has, for years, raised a number of concerns about GMOs. Most stem from an idea called the precautionary principle, which could be summed up as First, do no harm. Or in this case, we should prove a new technology wont create big, messy health problems before we unleash it on the public. (It was this idea that led Zambian scientists to recommend that their government reject GMO corn.)

UCS isnt alarmist about GMOs: There is a lot we dont know which is no reason for panic, but a good reason for caution. The organization identifies a few possible concerns about genetic engineering.

The rest is here:
Opinion: GMOs: Time bombs in our food supply?

Smokers are more likely to have children who also smoke, even if they quit before their child was born, MedPage Today reported.

In a study published in the journal Pediatrics, researchers discovered that the children of people who smoked only in their teenage years were still 3.2 times more likely to also pick up the habit, compared to children whose parents had never smoked.

For the study, researchers gathered data from a sample of ninth grade students in St. Paul, Minn. They followed this group from 1988 through age 38 - and then also gathered data from the children of that cohort, starting at age 11.

Overall, they found the rate of smoking was 23 to 29 percent among kids ages 11 and older whose parents had once smoked or currently smoked, compared with 8 percent among children of parents who had never smoked, MedPage Today reported. Children who had older siblings who smoked were also more likely to smoke, researchers reported.

"We don't know exactly what's going on here, but my hypothesis is that there is a genetic predisposition toward smoking, Dr. John Spangler, a family and community medicine specialist at Wake Forest Baptist Medical Center in Winston-Salem, N.C., told MedPage Today. Whether it is a genetic predisposition toward risk taking behavior, genetic disposition toward experimentation of substances, or even a genetic disposition toward nicotine addiction itself.

However, Spangler noted that parents can still take action to prevent their children from taking up the unhealthy habit.

A parent should take the opportunity to make it a teachable moment," Spangler said. "There's nothing you can do about your past history of smoking; there is something you can do about your current history of smoking. But if you talk and engage the child in a healthy lifestyle, it may make you more likely to quit and also make the child less likely to start smoking."

The studys authors noted that their research had some limitations including: relatively low levels of education, the fact that only one parent provided information on their smoking history and the inability to determine exactly what caused the link.

Click for more from MedPage Today.

Read this article:
Urge to start smoking could be genetic, study says

Integrating Genetics and Ecology into Restoration Practice for Chesapeake Bay Seagrasses
The National Socio-Environmental Synthesis Center (SESYNC) Seminar presented by Dr. Maile Neel Associate Professor and Director, Norton-Brown Herbarium, Depa...

By: sesync annapolis

More:
Integrating Genetics and Ecology into Restoration Practice for Chesapeake Bay Seagrasses - Video

Human genetics Embryology Journals OMICS Publishing Group
This video is about human genetics which describes the study of inheritance as it occurs in human beings. Embryology is a science which is about the developm...

By: omicsgroupinc

See the rest here:
Human genetics

ITS NOT GENETICS . . . .
MTOF -MUSCLE TAKE OVER FAMILY OUR GOAL IS TO GO EVEN FURTHER BEYOND.....WE ARE FOCUSED EVERY STEP OF THE WAY TURNING THOSE WHO DOUBT OUR CAPABILITIES INTO FI...

By: MTOSupeRNaturaL

See the original post:
ITS NOT GENETICS . . . . - Video

Nature vs. Nurture

The role of genetics in athletic prowess

The Sports Gene by David Epstein

Are Michael Phelps and Serena Williams genetically predisposed to succeed athletically, or is their success purely a function of years of intense training? Is sprinter Usain Bolt the most naturally gifted athlete the world has ever seen, as his Web site contends, or did practice and community support contribute to his success? Are there genes for speed, strength and endurance, or can these traits be honed over time?

In The Sports Gene, David Epstein, a senior writer at Sports Illustrated, takes on the nature vs. nurture debate in the context of athletic ability. Epstein looks at the success stories of Olympic marathoners, high jumpers, professional baseball players and others, and examines studies about the effects of various factors on athletic development. The book covers variables such as eyesight, leg length and thickness, aerobic capacity, physical training and the use of human growth hormone.

Epstein also looks at training theories, such as the 10,000-hour rule popularized in Malcolm Gladwells Outliers, which holds that 10,000 hours of practice can make anyone an expert in a given field. He writes that there is some evidence to support this theory, but it doesnt tell the whole story. For example, Major League Baseball players spend thousands of hours honing their skills but Epstein found that on the whole, they also have exceptional eyesight.

Epstein points to data indicating that some people have the genetic potential to benefit from intense practice while others will make marginal but not stellar improvements, no matter how hard or how long they work. That is why two people can follow identical training plans and see drastically different results, he says.

So which is it: nature or nurture? Epstein concludes that one is useless without the other. Most athletic traits, he writes, are a braid of nature and nurture so intricately and thoroughly intertwined as to become a single vine.

Smithsonian

National Air and Space Museum takes three looks at art and science of space

Original post:
Nature or nurture? A new book looks at sports and genetics.

CAMBRIDGE, U.K. and IPSWICH, Mass., Aug. 5, 2013 /PRNewswire/ --Population Genetics Technologies Ltd (PGT) and New England Biolabs, Inc. (NEB) announce that PGT has assigned exclusive rights to a patent (US 8,420,319) covering methods for asymmetric adaptor library construction to NEB. As part of next generation sequencing (NGS) library preparation, this technology enables increased efficiency at the adaptor ligation step, resulting in high yield libraries and minimized adaptor-dimer formation. In conjunction with NEB's other innovations in NGS library preparation, this patent further strengthens the NEBNext product portfolio.

(Logo: http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b )

Commenting on the deal, Population Genetics' Chief Operating Officer, Frank Massam said, "Given the incredible expansion of genome sequencing and nucleic acid-based assays, methods that simplify and improve nucleic acid manipulation and analysis are of high value. We are therefore delighted that some of the methods we have invented and developed can now be made available to a larger customer base via NEB's global distribution network. This partnership fits well with our strategy of engaging with partners to fully realize the value of our technologies and capability." Financial terms were not disclosed.

NEB's Executive Director of Global Business Development, Peter Nathan added, "We are pleased that Population Genetics recognizes NEB's strong market position in NGS and are excited to offer a novel adaptor solution for NGS library preparation to our customers. The increased efficiencies resulting from use of this process further enhance the workflows for our NEBNext library construction kits."

NEBNext products are a series of highly pure and cost-effective reagents that facilitate DNA and RNA library preparation for downstream applications, such as next generation sequencing. The recently launched NEBNext Ultra kits, which address the increasing need for fast and robust performance, also allow the use of low nanogram amounts of input DNA or RNA.

For more information on NEBNext reagents for library preparation, visit NEBNext.com.

NEBNEXT is a registered trademark of New England Biolabs, Inc. Ultra is a trademark of New England Biolabs, Inc.

About Population Genetics Technologies Ltd

Population Genetics Technologies Ltd was founded in 2005 by Nobel Laureate Dr Sydney Brenner; the founder of Applied Biosystems and of Lynx Therapeutics, Dr Sam Eletr; and the founder of Molecular Tool and Red Abbey Ventures, Dr Philip Goelet. The company has developed proprietary technologies that transform the economic viability of performing large scale genetic population studies, and that allow the sensitive and high confidence detection of rare variants and mutations for use in research and in guiding clinical decision making.

About New England Biolabs

The rest is here:
Population Genetics Assigns Asymmetric Adaptor Library Construction Patent To New England Biolabs

SEATTLE, WA--(Marketwired - Aug 5, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, said that the new ASCO clinical practice guideline for the use of pharmacologic interventions for breast cancer risk reduction, published on July 8, 2013, by the American Society for Clinical Oncology (ASCO), is an important step forward in the fight to prevent breast cancer. However, Atossa believes that the potentially serious side effects associated with the prophylactic use of tamoxifen, raloxifene, arzoxifene, lasofoxifene, exemestane, or anastrozole, which include endometrial cancer, blood clots, stroke, ovarian cysts and cataracts, must be carefully weighed against the potential benefits and carefully targeted to the high risk patients most likely to benefit.

The new ASCO clinical practice guideline is based on the recommendations of the U.S. Preventative Services Task Force and a systematic review of randomized controlled trials and meta-analyses published from June 2007 through June 2012. The guideline encourages physicians to discuss the option of chemoprevention for women at increased breast cancer risk, defined as individuals with a 5-year projected absolute risk of BC 1.66% (based on the National Cancer Institute BC Risk Assessment Tool or an equivalent measure) or women diagnosed with lobular carcinoma in situ. The guideline also recommends that physicians discuss the specific risks and benefits associated with each chemopreventive agent with their patients.

Dr. Steven C. Quay, Chairman, President and CEO of Atossa Genetics, commented, "While we agree that the data support the use of chemopreventive agents for the prevention of breast cancer in certain cases, we also believe that a woman at high risk for breast cancer due to family history should have our evidence-based ForeCYTE Breast Health Test before making any treatment decision. The fact is that more than 85 percent of women who develop breast cancer have no family history and therefore family history alone is not a reliable or sufficient indicator of true breast cancer risk. Only cytological examination of cells from the linings of the milk ducts and lobules of the breast can scientifically determine whether a woman needs to be especially concerned about her risk. These specimens can be obtained either by a surgical or core needle biopsy or non-invasively with the ForeCYTE Breast Health Test."

Atossa's ForeCYTE Breast Health Test is a non-invasive, quick and painless procedure performed in a doctor's office by a nurse or physician's assistant. The test collects samples of Nipple Aspirate Fluid from the patient's breasts that contain cells from the milk ducts and lobules and then the samples are sent to Atossa's National Reference Laboratory for Breast Health for cytological examination. A patient-friendly report with results and treatment recommendations is then generated for the doctor and patient.

The analysis of those duct cells, from which approximately 95 percent of cancers develop, can show that a woman who is deemed to be at high risk because of family history may actually be perfectly healthy, and thus does not require preventive drug treatment or other interventions. Alternatively, the analysis in a woman with no family history may detect pre-cancerous changes -- up to eight years before a tumor is large enough to be spotted on a mammogram. By more effectively determining a woman's true risk for breast cancer, more informed treatment decisions can be made.

"In addition to considering women thought to be at high risk for breast cancer, I believe in the use of Atossa's evidence-based ForeCYTE test to more accurately assess a woman's breast health status and breast cancer risk for those women thought to be at low risk. By identifying a woman's real risk, we will ensure that women who can truly benefit from treatment with chemotherapeutic agents will get treated, while women at normal risk can be spared from the potential side effects," said Dr. Jonathan Herman of Elite Women's Healthcare, based in Lake Success, New York.

"I have found in my practice that the great majority of the women who have had the ForeCYTE test are pleased with the ease and convenience of the sample collection process and the informative, user-friendly report that is generated. I encourage all physicians to utilize the ForeCYTE test in their practices for the benefit of their female patients," Dr. Herman concluded.

About the ForeCYTE Breast Health Test

The ForeCYTE Breast Health Test, intended for the 110 million women in the U.S. ages 18 to 73, is a painless, quick and non-invasive procedure that can be done in a physician's office. A small sample of fluid, aspirated from the nipple of each breast with the Company's modified breast pump, can provide vital early detection of cancer or pre-cancerous conditions that may progress to cancer over an approximately eight year period and before cancer can be detected by mammography or other means and without the risks of radiation, especially in women younger than age 50. No invasive biopsy needles or open surgical incisions are used in the Atossa test and the test is painless.

Just as the Pap smear has reduced cervical cancer rates by over 70 percent, becoming the most successful screening test in medicine, the goal of Atossa Genetics is to reduce the stubbornly high rate of breast cancer through the early detection of the precursor changes that can lead to breast cancer and the treatment of those early changes.

See more here:
New ASCO Clinical Practice Guideline for Breast Cancer Risk Reduction May Be Insufficient for Widespread Reduction ...

Quarterly Revenue Growth Accelerates to 60% YoYExcluding Grant Revenue, Quarterly Revenue Grew 90% YoYGross Margin Improved to 30% From 5% in the Year Ago PeriodQuarterly Clinical Test Volume Increased 97% YoY

RUTHERFORD, N.J., Aug. 5, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based cancer diagnostics, reported financial results for the second quarter ended June 30, 2013.

Second Quarter Financial Highlights:

Revenue for the second quarter of 2013 increased 60% to $1.8 million, compared with $1.1 million in the second quarter of 2012.

Clinical test volume increased 97% to 3,204 tests in the second quarter, compared with 1,623 tests in the second quarter of 2012.

Gross profit increased 792% to $553,000 in the second quarter, from $62,000 for the same period of 2012, while gross margin improved to 30% compared to 5% in the second quarter of 2012 and 12% for the first quarter of 2013.

Operating expenses were unchanged at $2.3 million in the second quarter, compared to the same period of 2012. R&D expense for the second quarter decreased 13% to $456,000, compared to $527,000 in the second quarter of 2012. Sales and marketing expense increased 19% to $447,000 in the second quarter, from $376,000 in the year-ago period.

Loss from operations in the second quarter decreased 22% to $1.7 million, compared to $2.2 million in the same period of 2012.

Adjusted for one-time IPO-related debt conversion costs, net loss for the second quarter was $2.3 million, compared to a net loss of $1.9 million, in the second quarter of 2012. This increase in loss was primarily the result of expense related to a $170,000 decrease in the fair value of derivative warrant liability, as compared with $1.5 million in non-cash income related to an increase in fair value of derivative warrant liability in the second quarter of 2012. Interest expense decreased from $1.1 million in the second quarter of 2012 to $388,000 in the second quarter of 2013. GAAP net loss for the second quarter of 2013 was $9.1 million compared to a loss of $1.9 million for the second quarter of 2012.

Six-Month Financial Highlights:

Link:
Cancer Genetics Announces Second Quarter 2013 Financial Results

Advanced Topics - Stem Cell Therapy part 1

By: Jesse Matteson

Visit link:
Advanced Topics - Stem Cell Therapy part 1 - Video

Genetic engineering seed company Kaiima Ltd. is in the final stages of a financing round from Asian investors, including Horizon Ventures of Hong Kong billionaire Li Ka-Shing, the chairman of Hutchison Whampoa Ltd. (HKSE: 0018). The World Bank has pledged up to $20 million out of the $50 million that Kaiima plans to raise.

Current Kaiima investors, including US funds Kleiner Perkins Caufield & Byers and Draper Fisher Juvetson and its Israeli affiliate DFJ Tamir Fishman Ventures Ltd. (TASE: TFVC), are also due to participate in the financing round.

Kaiima develops improved varieties of crops using a proprietary "advanced ploidy" technology to replicate a crop's genome, not modifying it through genetic engineering. The company says that it can create bigger plants that are richer in nutrients, able to photosynthesize faster, survive in extreme and drought conditions, and generate more seeds for the faster propagation of the next generation.

Kaiima's capabilities have been demonstrated with various crops, but it currently focuses on rice, corn, wheat, rapeseed (an alternative to canola), and the castor oil plant. Caster oil is a leading biodiesel product, and the company already sells a variety with higher oil concentration (double the amount of oil per hectare, it says).

Genetic engineering of crops has been gaining ground among Israeli start-ups. Evogene Ltd. (TASE:EVGN) has major cooperation agreements with Monsanto Corporation (NYSE: MON), Dupont (NYSE: DD) unit Pioneer Hi-Bred, and Syngenta AG (SWX: SYNN; NYSE: SYT); and Rosetta Green was acquired by Monsanto earlier this year for $35 million.

Kaiima uses a different business model and has no cooperation agreements with the seed giants. Instead, it has raised, and continues to raise, substantial amounts of capital, apparently in order to bring products to market independently, as it did with rapeseed.

Kaiima is currently focused on China, which is apparently why it approached the investors mentioned above. The company is also targeting India, and it plans to collaborate with the Indian government. Over the coming year, it plans to find a distributor in India and China, produce its own products, and launch large-scale sales a few years later.

Kaiima was founded in 2006 by CEO Dr. Doron Gal, who has a doctorate in Geophysics from Stanford University.

Published by Globes [online], Israel business news - http://www.globes-online.com - on August 4, 2013

Copyright of Globes Publisher Itonut (1983) Ltd. 2013

Read the original here:
Seed breeding co Kaiima raising $50m

(Francisco Kjolseth | The Salt Lake Tribune) Mary Bronner, division chief of anatomic pathology at the Huntsman Cancer Institute, describes the inner workings of the Sequenom instrument, which in part can detect gene mutations for cancers.

Cancer care 2 hospitals aim to screen all patients for genetic mutations for which specialized, or targeted, therapies exist.

On Mary Bronners desk at the Huntsman Cancer Institute stands a microscope for identifying and categorizing cancer cells.

About 99 percent of the diagnostic work by her team of pathologists is done with this centuries-old tool.

Genetic sequencing in research

Researchers are using genetic sequencing to speed delivery of new drugs, and to prevent disease from taking hold in patients with a family history of cancer, blurring the line between research and medicine.

Drug trials

At Huntsman Cancer Institute, researchers just wrapped up a clinical trial on a new lung cancer drug. Sequencing was used to screen 200 patients to find the 5 to 10 percent who carried the genetic change that made them a candidate for the trial.

Such studies are expanding the arsenal of available drugs, said Sunil Sharma, chief medical oncologist and director of clinical research at Huntsman. If this drug was tested in 100 lung cancer patients it would have been deemed a failure.

View post:
Cancer care in Utah goes genetic

Genetics? - Bodybuilding Tips To Get Big
Leroy Colbert is the first man to develop 21 inch arms and is in the Bodybuilding Hall of Fame for doing so. He has over 60 years in the business of health and building bodies. He is very knowledge...

By: mryorkielover

More:
Genetics? - Bodybuilding Tips To Get Big - Video

Genetic Syndromes Gene Therapy Journals OMICS Publishing Group
This video belongs to Genes which are the basic physical and functional units of hereditary and are the specific sequences of bases that are carried on chrom...

By: omicsgroupinc

Link:
Genetic Syndromes

NewsLife: PCP pushes for more studies on stem cell therapy
NewsLife - PCP pushes for more studies on stem cell therapy (Reported By: Dina Paguibitan) - [July 30, 2013] For more news, visit: #9659;http://www.ptvnews.ph Dow...

By: PTV PH

See the article here:
NewsLife: PCP pushes for more studies on stem cell therapy - Video

OMICS Group Cell Therapy 2012 Opeing Ceremony

By: omicsgroupinc

Follow this link:
OMICS Group Cell Therapy 2012 Opeing Ceremony - Video

By Traci Pedersen Associate News Editor Reviewed by John M. Grohol, Psy.D. on August 2, 2013

A new discovery has changed the way scientists think about non-inherited schizophrenia.

Rather than individual gene mutations being responsible for schizophrenia on their own, its more likely that a gene mutation can damage an entire neural pathway, which creates a ripple effect across networks as the brain develops, according to researchers at the University of Washington.

In fact, what is now known as one disease (schizophrenia) may actually be many different diseases.

Processes critical for the brains development can be revealed by the mutations that disrupt them, saidMary-Claire King, Ph.D., a UW grantee working on the project. Mutations can lead to loss of integrity of a whole pathway, not just of a single gene.

The new research supports the current and relatively new model of schizophrenia as a neurodevelopmental disorder in which psychosis is a late, potentially preventable stage of the illness.

In the study, researchers were able to trace back spontaneous gene mutations to where and when they likely caused brain damage.

They found that some individuals might develop the precursors for schizophrenia even before birth, because their brains produced damaged neurons as a developing fetus.

Previous research had already found a connection between gene mutations and non-inherited schizophrenia that could be traced to genes involved in brain development. Until now, however, scientists knew little about how those gene mutations interact and affect pathways in the brain.

For the study, researchers chose to focus on these pathways using an online tool called the transcriptome an atlas of human brain development that shows where in the brain and when in development genes turn on.

See the rest here:
In Schizophrenia, Single Mutation May Damage Entire Brain Pathway

The Kansas Corn Commission hopes a website run by the agriscience industry will put fears about genetically modified crops to rest.

GMOAnswers.com, sponsored by bioscience companies BASF, Bayer CropScience, Dow AgroSciences LLC, DuPont, Monsanto Co. and Syngenta, includes information on genetic engineering in crops and allows members of the public to ask questions about the process and the safety of genetically engineered foods.

Kansas corn commissioner Ken McCauley said organic farmers and some environmentalists have put out arguments against genetically modified foods that arent supported by science, and corn farmers who use modified seeds want to give their side. About 88 percent of the corn grown in the United States is grown from genetically modified seeds, according to the corn commission.

So many times individuals or groups can say anything without any data or backup, he said.

The Kansas Organic Producers Association didnt return a call seeking comment. Organic farmers, by definition, cant grow genetically modified crops.

Genetic modification involves creating desirable traits in plants, such as resistance to drought or insects, by combining DNA from other organisms with the crop. Farmers have crossed similar plants to produce desired crops for centuries, but the advent of genetic engineering makes it possible to use genes from very different plants or even bacteria or other types of organisms.

The Food and Drug Administration has to approve the safety of new genetically modified plants, and other government agencies evaluate their environmental impact. The FDA doesnt conduct the tests itself, but it evaluates studies performed by the company that developed the seed the same process it uses to decide whether to allow new drugs on the market. If genetically modified seeds are determined to be substantially equivalent to existing foods, they are evaluated in the same way as traditional foods, according to an overview of issues related to genetically modified foods published in 2008 in the scientific journal Annual Review of Plant Biology.

Testing safety by having animals consume the genetically modified food and a test group consume its traditional equivalent can be done, the article said, but it is relatively rare because of the large amounts animals would have to eat to conduct a test. Analysis to determine whether the engineered plant produces any substances known to be toxic or cause allergies is more common. A plan to alter the protein content of soybeans was halted after the possibility it would cause reactions in people allergic to Brazil nuts, the Review of Plant Biology article said.

View post:
Kansas Corn Commission hails GMO website

Genetics, Epigenetics, Biology and the Emotions. Chris Astill-Smith - Chapter 2 of 9

By: Clive Bingham

Excerpt from:
Genetics, Epigenetics, Biology and the Emotions. Chris Astill-Smith - Chapter 2 of 9 - Video

Genetics, Epigenetics, Biology and the Emotions. Chris Astill-Smith - Chapter 3 of 9

By: Clive Bingham

View original post here:
Genetics, Epigenetics, Biology and the Emotions. Chris Astill-Smith - Chapter 3 of 9 - Video

ageLOC TR90 Opportunity - Weight Loss at Genetics

By: agelocmillet

See more here:
ageLOC TR90 Opportunity - Weight Loss at Genetics - Video

Genetics, Epigenetics, Biology and the Emotions. Chris Astill-Smith - Chapter 7 of 9

By: Clive Bingham

Original post:
Genetics, Epigenetics, Biology and the Emotions. Chris Astill-Smith - Chapter 7 of 9 - Video

Genetics, Epigenetics, Biology and the Emotions. Chris Astill-Smith - Chapter 9 of 9

By: Clive Bingham

See the rest here:
Genetics, Epigenetics, Biology and the Emotions. Chris Astill-Smith - Chapter 9 of 9 - Video

Genetics and Plant Breeding in Interwar Britain: A Double Forgetting of History
This is a paper I presented at the 24th International Congress of History of Science, Technology and Medicine, held in Manchester. A huge thank you to all th...

By: Dominic Berry

Excerpt from:
Genetics and Plant Breeding in Interwar Britain: A Double Forgetting of History - Video

Don #39;t Fight Your Genetics
Video reveals the best diet to lose weight http://www.thephysiqueformula.com Want to build muscle? Hire jimmy http://www.jimmysmithtraining.com What suppleme...

By: jimmysmithtraining

View post:
Don't Fight Your Genetics - Video